This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Winners And Losers in CLL at ASCO '13

Stocks in this article: GILD INFI ABBV RHHBY PCYC

NEW YORK ( TheStreet) -- New products in development for chronic lymphocytic leukemia (CLL), an incurable B-cell cancer, will transform the treatment of this disease over the next few years.

CLL offers a big market opportunity as more than 150,000 people in the U.S. and Europe have the disease, and about a third of these require first or second-line therapy.

After PD-1/PD-L1 immunotherapy, CLL was one of the hottest topics at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago last weekend.

Some of the companies with interesting new CLL data at the meeting included Gilead Sciences (GILD), Roche (RHHBY), Infinity Pharmaceuticals (INFI) and AbbVie (ABBV).

A key drug in development for CLL, albeit one with little new data at ASCO, was the Bruton kinase inhibitor ibrutinib from Pharmacyclics (PCYC) and Johnson & Johnson (JNJ). Ibrutinib data had already been presented at prior conferences. Approval for ibrutinib in mantle cell lymphoma (MCL) is highly likely by the end of the year -- a point made by TheStreet contributor David Sobek in a recent column.

Celgene's (CELG) development activities in CLL was also missing from ASCO this year. There was no mention of the phase III trial for Revlimid in CLL or any data on AV-292, a potential competitor to ibrutinib that Celgene obtained with the purchase of Avila Therapeutics last year.

Here are my winners and losers in CLL from this year's ASCO meeting:

Winner: Gilead's Idelalisib

Gilead had some of the most impressive CLL data at ASCO. Of particular note were the results from the phase II clinical trial of idelalisib, a targeted, highly selective, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta, in combination with rituximab in frontline CLL. The data are particularly meaningful because patients enrolled in this trial were not cherry-picked to be those who were the fittest and most likely to respond. Patients were elderly (median age 71) with existing medical conditions, more typical of the majority of CLL patients seen in community practice.

Dr. Susan O'Brien from the University of Texas M.D. Anderson Cancer Center in Houston presented data that showed significant efficacy -- highlighted by a rapid reduction in size of lymph nodes. Nineteen percent of the 74 patients in the trial achieved a complete response and 78 percent a partial response.

At 24 months, 93 percent of patients had not seen their disease progress. The addition of rituximab to idelalisib also removed the raised lymphocyte count (lymphocytosis) seen with idelalisib when used on its own, suggesting a combination strategy offers significant clinical benefit.

These data were a big win for Gilead at ASCO.

Winner: Roche's Obinutuzumab (GA101)

Roche is developing a novel, next-generation anti-CD20 monoclonal antibody -- obinutuzumab (GA101) -- with potentially greater efficacy than its predecessor Rituxan.

In the preliminary results of a phase III trial, Roche showed adding obinutuzumab to the chemotherapy chlorambucil offered significant benefit. This trial was also undertaken in an elderly patient population with co-morbidities who would not be eligible to receive standard chemoimmunotherapy with fludarabine and cyclophosphamide (FC) with or without Rituxan.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs